Duration of antiplatelet drugs for drug-eluting stents studied

September 20, 2012
Duration of antiplatelet drugs for drug-eluting stents studied
In patients receiving drug-eluting stents, dual antiplatelet therapy can be safely discontinued during the first year, according to two studies published online Sept. 19 in the Journal of the American College of Cardiology.

(HealthDay)—In patients receiving drug-eluting stents, dual antiplatelet therapy can be safely discontinued during the first year, according to two studies published online Sept. 19 in the Journal of the American College of Cardiology.

In the first study, Ignacio Ferreira-González, M.D., Ph.D., from Vall d'Hebron Hospital in Barcelona, Spain, and colleagues conducted a study involving 1,622 patients undergoing drug-eluting stent implantation. The patients were assessed at regular intervals up to a year post-implantation. During that time, 10.6 percent interrupted at least one antiplatelet drug; 64.5 percent of the interruptions were temporary. The researchers found that the rate of major cardiac events was similar in patients who continued or interrupted treatment.

In the second study, Byeong-Keuk Kim, M.D., from the Yonsei University College of Medicine in Seoul, South Korea, and colleagues randomly assigned 2,117 patients with coronary artery stenosis to receive a zotarolimus-eluting stent with three months of dual or another drug-eluting stent with twelve months of dual antiplatelet therapy. The researchers found that both groups had similar rates of a primary composite end point of , , stent thrombosis, target or vessel revascularization, or bleeding at one year (4.7 percent in each group).

"With newer-generation drug-eluting stents, six months [of] dual antiplatelet therapy might be sufficient, and three months not completely off-the-wall in low-risk groups," Bernhard Witzenbichler, M.D., from Charité-Campus Benjamin Franklin in Berlin, writes in an accompanying editorial. "However, the patient- and device-related criteria safely allowing early dual antiplatelet therapy withdrawal or interruption still have to be determined."

The Ferreira-González study was partially funded by Bristol-Myers Squibb; two authors disclosed financial ties to drug and device companies. Two authors from the Kim study disclosed to Medtronic.

Explore further: Results of the DESERT registry reported at TCT 2011

More information: Abstract - Ferreira-González
Full Text
Abstract - Kim
Full Text
Editorial

Related Stories

Results of the DESERT registry reported at TCT 2011

November 9, 2011
The risk of late stent thrombosis (ST) in the first generation of drug-eluting stents continues for up to seven years after implantation, and certain types of patients, including smokers and those who are younger, are at ...

Assessing the most appropriate duration of dual antiplatelet therapy after coronary stenting

August 30, 2011
A randomised multicentre open-label study evaluating the efficacy and safety of prolonged antiplatelet therapy in patients with coronary disease has found that 24 months' duration of dual therapy is no better than six months ...

Drug-Eluting stents reduce risk of thrombosis

March 23, 2012
(HealthDay) -- Cobalt-chromium everolimus eluting stents (CoCr-EES) are associated with a significantly lower rate of stent thrombosis within two years of implantation, compared with other bare-metal and drug-eluting stents, ...

Results of the EVOLVE trial reported at TCT 2011

November 11, 2011
A clinical trial has established the non-inferiority of a drug-eluting stent with a bioabsorbable polymer compared to a drug-eluting stent with a durable polymer. Results of the EVOLVE clinical trial were presented today ...

Low and comparable rates of stent thrombosis found with zotarolimus- and sirolimus-eluting stents

August 27, 2012
Rates of stent thrombosis at three years were low and comparable between zotarolimus-eluting and sirolimus-eluting stents, according to findings from the PROTECT study described here today at ESC Congress 2012.

Recommended for you

New molecule may hold the key to triggering the regeneration and repair of damaged heart cells

August 21, 2017
New research has discovered a potential means to trigger damaged heart cells to self-heal. The discovery could lead to groundbreaking forms of treatment for heart diseases. For the first time, researchers have identified ...

Researchers investigate the potential of spider silk protein for engineering artificial heart

August 18, 2017
Ever more people are suffering from cardiac insufficiency, despite significant advances in preventing and minimising damage to the heart. The main cause of reduced cardiac functionality lies in the irreversible loss of cardiac ...

Lasers used to detect risk of heart attack and stroke

August 18, 2017
Patients at risk of heart attacks and strokes may be spotted earlier thanks to a diagnosis tool that uses near-infrared light to identify high-risk arterial plaques, according to research carried out at WMG, University of ...

Cholesterol crystals are sure sign a heart attack may loom

August 17, 2017
A new Michigan State University study on 240 emergency room patients shows just how much of a role a person's cholesterol plays, when in a crystallized state, during a heart attack.

How Gata4 helps mend a broken heart

August 15, 2017
During a heart attack, blood stops flowing into the heart; starved for oxygen, part of the heart muscle dies. The heart muscle does not regenerate; instead it replaces dead tissue with scars made of cells called fibroblasts ...

Injectable tissue patch could help repair damaged organs

August 14, 2017
A team of U of T Engineering researchers is mending broken hearts with an expanding tissue bandage a little smaller than a postage stamp.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.